These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 14668046)

  • 1. Trophic factors and cytokines in early diabetic glomerulopathy.
    Brosius FC
    Exp Diabesity Res; 2003; 4(4):225-33. PubMed ID: 14668046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease.
    Flyvbjerg A
    Diabetologia; 2000 Oct; 43(10):1205-23. PubMed ID: 11079738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic nephropathy: where hemodynamics meets metabolism.
    Forbes JM; Fukami K; Cooper ME
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?
    Gilbert RE; Cooper ME
    Kidney Int; 1999 Nov; 56(5):1627-37. PubMed ID: 10571771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The renal endothelium in diabetic nephropathy.
    Eleftheriadis T; Antoniadi G; Pissas G; Liakopoulos V; Stefanidis I
    Ren Fail; 2013; 35(4):592-9. PubMed ID: 23472883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy.
    Heilig CW; Deb DK; Abdul A; Riaz H; James LR; Salameh J; Nahman NS
    Am J Nephrol; 2013; 38(1):39-49. PubMed ID: 23817135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy.
    Wang SN; LaPage J; Hirschberg R
    Kidney Int; 2000 Mar; 57(3):1002-14. PubMed ID: 10720953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology.
    Wolf G
    Eur J Clin Invest; 2004 Dec; 34(12):785-96. PubMed ID: 15606719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.
    Iglesias-de la Cruz MC; Ziyadeh FN; Isono M; Kouahou M; Han DC; Kalluri R; Mundel P; Chen S
    Kidney Int; 2002 Sep; 62(3):901-13. PubMed ID: 12164872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of diabetic renal hypertrophy.
    Wolf G; Ziyadeh FN
    Kidney Int; 1999 Aug; 56(2):393-405. PubMed ID: 10432377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment?
    Dei Cas A; Gnudi L
    Metabolism; 2012 Dec; 61(12):1666-73. PubMed ID: 22554833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy.
    Rossert J; Terraz-Durasnel C; Brideau G
    Diabetes Metab; 2000 Jul; 26 Suppl 4():16-24. PubMed ID: 10922969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
    Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A
    Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.
    Elmarakby AA; Sullivan JC
    Cardiovasc Ther; 2012 Feb; 30(1):49-59. PubMed ID: 20718759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor and diabetic nephropathy.
    Chen S; Ziyadeh FN
    Curr Diab Rep; 2008 Dec; 8(6):470-6. PubMed ID: 18990304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
    Ito T; Tanimoto M; Yamada K; Kaneko S; Matsumoto M; Obayashi K; Hagiwara S; Murakoshi M; Aoki T; Wakabayashi M; Gohda T; Funabiki K; Maeda K; Horikoshi S; Tomino Y
    Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195.
    Tsuchida K; Makita Z; Yamagishi S; Atsumi T; Miyoshi H; Obara S; Ishida M; Ishikawa S; Yasumura K; Koike T
    Diabetologia; 1999 May; 42(5):579-88. PubMed ID: 10333051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenesis of diabetic nephropathy.
    Dronavalli S; Duka I; Bakris GL
    Nat Clin Pract Endocrinol Metab; 2008 Aug; 4(8):444-52. PubMed ID: 18607402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes.
    Stieger N; Worthmann K; Teng B; Engeli S; Das AM; Haller H; Schiffer M
    Metabolism; 2012 Aug; 61(8):1073-86. PubMed ID: 22365040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
    Mizuno S; Nakamura T
    Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.